Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;15(7):3533-3537.
doi: 10.21037/jtd-23-699. Epub 2023 Jun 15.

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds

Paul R Walker  1
Affiliations
Editorial

Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds

Paul R Walker. J Thorac Dis. .
No abstract available

Keywords: Circulating tumor DNA (ctDNA); immunotherapy; neoadjuvant; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-699/coif). The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
A potential paradigm of utilizing pre-surgical ctDNA to guide neoadjuvant or adjuvant treatment decisions in operable NSCLC. ctDNA, circulating tumor DNA; IO, immune oncology; chemo-IO, chemotherapy-immune oncology; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
See this image and copyright information in PMC

Comment on

References

    1. Shinohara S, Takahashi Y, Masago K, et al. The beginning of a new era in induction treatment for operable non-small cell lung cancer: a narrative review. J Thorac Dis 2023;15:747-58. 10.21037/jtd-22-957 - DOI - PMC - PubMed
    1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60. 10.1056/NEJMoa031644 - DOI - PubMed
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Zhang F, Guo W, Zhou B, et al. Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. J Thorac Oncol 2022;17:909-20. 10.1016/j.jtho.2022.04.012 - DOI - PubMed
    1. Rosner S, Reuss JE, Zahurak M, et al. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 2023;29:705-10. 10.1158/1078-0432.CCR-22-2994 - DOI - PMC - PubMed